# SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

> **NCT07234721** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 9 (estimated)

## Conditions studied

- Relapsed and Refractory Multiple Myeloma (RRMM)

## Interventions

- **DRUG:** SL4903 Autologous T-Cell Injection
- **DRUG:** SL4903 Autologous T-Cell Injection
- **DRUG:** SL4903 Autologous T-Cell Injection

## Key facts

- **NCT ID:** NCT07234721
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-03-20
- **Final completion:** 2028-10-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234721, "SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07234721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*